Propofol in COVID 19 - From basic science to clinical impact
- PMID: 32712236
- PMCID: PMC7347356
- DOI: 10.1016/j.ajem.2020.07.011
Propofol in COVID 19 - From basic science to clinical impact
Comment in
-
The authors' response: Propofol in COVID 19: From basic science to clinical impact.Am J Emerg Med. 2021 Jul;45:528. doi: 10.1016/j.ajem.2020.07.006. Epub 2020 Jul 9. Am J Emerg Med. 2021. PMID: 32690223 Free PMC article. No abstract available.
Comment on
-
Neuroleptic malignant syndrome in patients with COVID-19.Am J Emerg Med. 2020 Oct;38(10):2243.e1-2243.e3. doi: 10.1016/j.ajem.2020.05.042. Epub 2020 May 22. Am J Emerg Med. 2020. PMID: 32473756 Free PMC article.
References
-
- Sohn J.T. Propofol and sedation in patients with coronavirus disease. PLoS One. 2018 Jul 11;13(7) doi: 10.1371/journal.pone.0199373. eCollection 2018. - DOI
-
- Murphy P.G., Myers D.S., Davies M.J., Webster N.R., Jones J.G. The antioxidant potential of propofol (2,6-diisopropylphenol) Br J Anaesth. 1992;68:613–618. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical